v3.26.1
Note 2 - Significant Accounting Policies (Details Textual)
3 Months Ended
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Amortization of above and below Market Leases $ 1,244 $ 1,022    
Deferred Costs 1,200,000   $ 1,300,000  
Operating Lease, Initial Direct Cost Expense, over Term 83,447 134,776    
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation 5,171,903   7,422,359  
Restricted Cash 3,600,000   5,700,000  
Deferred Offering Costs 287,666   279,603  
Marketable Securities 0      
Liabilities, Fair Value Disclosure 0   0  
Equity Securities, FV-NI 5,885   3,900  
Conduit Pharmaceuticals Inc [Member]        
Equity Securities, FV-NI $ 5,885   3,900 $ 3,900
Fair Value, Inputs, Level 1 [Member]        
Marketable Securities     $ 0  
Model Home [Member]        
Number of Properties Classified as Held for Sale 4      
Impairment of Real Estate   26,943    
Commercial Property [Member]        
Impairment of Real Estate $ 524,373      
Finite-lived Intangibles, Other Than Lease Intangibles [Member]        
Amortization of Intangible Assets $ 1,540 $ 13,145    
Maximum [Member]        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year) 5 years      
Minimum [Member]        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year) 1 year      
Leasehold Improvements [Member] | Maximum [Member]        
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation (Year) 10 years